title: [Clinical analysis of linezolid in treatment of infection with methicillin--resistant Staphylococcus in 14 neurosurgical patients].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of linezolid in the treatment of post-neurosurgical intracranial methicillin-resistant Staphylococcus (MRS) infection.
  
  
  METHODS
  The data from 14 patients, admitted to neurological intensive care unit (ICU) of Medical College of Chinese People's Armed Police Forces between March 2009 and November 2011, were retrospectively analyzed. All these cases suffered from post-neurosurgical intracranial infection by MRS and received linezolid treatment. Blood and cerebrospinal fluid (CSF) were collected before and 7 days and 14 days after treatment for routine and bacteriological examinations to assess clinical efficacy and adverse reactions of linezolid.
  
  
  RESULTS
  After 14-day treatment with linezolid, the clinical and laboratory parameters showed significant improvement: glucose (mmol/L) in CSF rose from 1.00 (0.65) to 3.15 (1.60), protein (mg/L) in CSF dropped from 2238.50 (2072.50) to 606.50 (217.30), white blood cell count [×10⁶/L] in CSF fell from 920.00 (1587.50) to 30.00 (40.00), and the number of patients with CSF neutrophil ratio>0.20 was reduced from 14 to 1 (all P < 0.01). In addition, serum procalcitonin level (μg/L) was significantly reduced from 0.65 (1.16) to 0.08 (0.09) after linezolid therapy (P < 0.01). Total effective rate was 85.7% (12/14), and CSF bacterial clearance rate reached 100%. No adverse events were found during the treatment.
  
  
  CONCLUSIONS
  Linezolid could effectively control post--neurosurgical intracranial MRS infection and alleviate the inflammatory responses with safety.
authors.affiliation: Department of Neurological Intensive Care Unit, Center for Neurology and Neurosurgery, Pingjin Hospital, Medical College of Chinese People's Armed Police Forces, Tianjin 300162, China.
authors.forename: Ming-liang
authors.initials: ML
authors.lastname: Zhao
authors.forename: Shi-zhong
authors.initials: SZ
authors.lastname: Sun
authors.forename: Xi-ping
authors.initials: XP
authors.lastname: Yang
authors.forename: Yue
authors.initials: Y
authors.lastname: Tu
authors.forename: Jian-jun
authors.initials: JJ
authors.lastname: Li
authors.forename: Tie-zhu
authors.initials: TZ
authors.lastname: Ma
authors.forename: Sai
authors.initials: S
authors.lastname: Zhang
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002494:Central Nervous System Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069349:Linezolid; D008297:Male; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000009:adverse effects; D023303:Oxazolidinones / Q000627:therapeutic use*; D011184:Postoperative Period; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid